SYRS Syros Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SYRS

Price (delayed)

$5.13

Market cap

$135.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.81

Enterprise value

$56.14M

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop ...

Highlights
SYRS's EPS is up by 22% year-on-year
Syros Pharmaceuticals's debt has decreased by 2.4% YoY
SYRS's revenue is down by 33% YoY but it is up by 13% QoQ
The gross profit is down by 33% year-on-year but it is up by 13% since the previous quarter
The equity has shrunk by 87% YoY and by 54% QoQ
SYRS's net income has plunged by 74% YoY and by 57% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://syros.com
Peers: OMER OMGA

Key stats

What are the main financial stats of SYRS
Market
Shares outstanding
26.45M
Market cap
$135.71M
Enterprise value
$56.14M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.49
Price to sales (P/S)
14.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.65
Earnings
Revenue
$9.94M
EBIT
-$159.45M
EBITDA
-$157.12M
Free cash flow
-$108.42M
Per share
EPS
-$5.81
Free cash flow per share
-$3.83
Book value per share
$0.79
Revenue per share
$0.35
TBVPS
$5.94
Balance sheet
Total assets
$168.17M
Total liabilities
$151.51M
Debt
$62.08M
Equity
$16.66M
Working capital
$108.3M
Liquidity
Debt to equity
3.73
Current ratio
3.95
Quick ratio
3.86
Net debt/EBITDA
0.51
Margins
EBITDA margin
-1,581.3%
Gross margin
100%
Net margin
-1,656.3%
Operating margin
-1,298.2%
Efficiency
Return on assets
-93.7%
Return on equity
-282.6%
Return on invested capital
-180.9%
Return on capital employed
-121.3%
Return on sales
-1,604.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SYRS stock price

How has the Syros Pharmaceuticals stock price performed over time
Intraday
-1.35%
1 week
1.79%
1 month
3.01%
1 year
71.57%
YTD
-34.15%
QTD
-4.11%

Financial performance

How have Syros Pharmaceuticals's revenue and profit performed over time
Revenue
$9.94M
Gross profit
$9.94M
Operating income
-$128.99M
Net income
-$164.57M
Gross margin
100%
Net margin
-1,656.3%
Syros Pharmaceuticals's net margin has shrunk by 160% YoY and by 39% QoQ
SYRS's net income has plunged by 74% YoY and by 57% from the previous quarter
The operating margin is down by 42% YoY but it is up by 17% from the previous quarter
SYRS's revenue is down by 33% YoY but it is up by 13% QoQ

Growth

What is Syros Pharmaceuticals's growth rate over time

Valuation

What is Syros Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.49
P/S
14.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.65
SYRS's EPS is up by 22% year-on-year
The P/B is 91% above the 5-year quarterly average of 3.4 and 91% above the last 4 quarters average of 3.4
The equity has shrunk by 87% YoY and by 54% QoQ
The price to sales (P/S) is 67% lower than the 5-year quarterly average of 44.3 but 15% higher than the last 4 quarters average of 12.7
SYRS's revenue is down by 33% YoY but it is up by 13% QoQ

Efficiency

How efficient is Syros Pharmaceuticals business performance
SYRS's ROS has dropped by 164% year-on-year and by 41% since the previous quarter
The ROE has plunged by 162% YoY and by 132% from the previous quarter
SYRS's return on invested capital has dropped by 124% year-on-year and by 84% since the previous quarter
SYRS's ROA has plunged by 100% YoY and by 74% from the previous quarter

Dividends

What is SYRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SYRS.

Financial health

How did Syros Pharmaceuticals financials performed over time
The total assets is 11% more than the total liabilities
The current ratio has declined by 43% year-on-year and by 8% since the previous quarter
Syros Pharmaceuticals's quick ratio has decreased by 43% YoY and by 6% QoQ
Syros Pharmaceuticals's debt to equity has surged by 117% QoQ
The equity has shrunk by 87% YoY and by 54% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.